GPT and metabolic dysfunction-associated steatotic liver disease: No significant differences were found in both AST and ALT between NAFLD patients with diabetes and those without diabetes who received pioglitazone therapy (AST: χ2 = 0.19, P = 0.66; ALT: χ2 = 0.16, P = 0.69; Supplementary Figure 1).